HP and mAbxience biosimilars represent a significant step forward in the application of artificial intelligence to optimize pharmaceutical production. At HP SCDS, we believe innovation should drive real impact—especially in areas where technology can truly make a difference, such as healthcare.

In this context, we, alongside mAbxience, have developed an artificial intelligence (AI)-based solution that optimizes the production of monoclonal antibodies and biosimilars, key treatments for thousands of patients worldwide.

The project was designed and validated in León. It is based on the creation of a digital twin of the biological process. In this way, teams can simulate, analyze, and enhance every stage of manufacturing using advanced neural network models and real production data.

As a result, production processes become more efficient, consistent, and predictable. In addition, this reduces variability and optimizes resource usage in complex industrial environments.

The goal is clear. It is to improve access to high-quality biologic therapies. Therefore, by optimizing production and shortening development timelines, AI helps bring critical treatments to patients faster.

This initiative is part of a strategic collaboration between HP SCDS and mAbxience. Moreover, it has the potential to scale across additional sites and continue driving innovation in biotechnology.

If you want to learn more about how we apply artificial intelligence in industrial environments, you can explore other initiatives on our website.